Please login to the form below

Not currently logged in
Email:
Password:

FDA warns Pfizer over adverse reporting

The US FDA has issued Pfizer with a warning letter relating to failures to report adverse events correctly

The US Food and Drug Administration (FDA) has issued Pfizer with a warning letter relating to failures to report adverse events correctly.

The letter, sent to Pfizer on May 26, follows an inspection of the company's New York premises by the US agency, which took place over a period of several weeks almost a year ago.

The inspection was to check Pfizer's procedures for conforming to the FDA's rules that adverse events must be reported to the authority within 15 days.

The letter contained reference to several instances where the pharma giant did not report adverse events relating to Lipitor (atorvastatin calcium) and Lyrica (pregabalin) at all. Further issues included the failure to report issues of visual disturbances as a result of a patient taking Viagra (sildenafil citrate) within the specified 15 day time period.

The US regulator also accused Pfizer of downgrading the classification of some reported events without justification.

In April 2010, the FDA warned Pfizer over its Geodon trials.

10th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics